BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhongsatiern J, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, Desai PB, Sherwin CM. Evaluation of Vancomycin Use in Late-Onset Neonatal Sepsis Using the Area Under the Concentration-Time Curve to the Minimum Inhibitory Concentration ≥400 Target. Ther Drug Monit 2015;37:756-65. [PMID: 26562817 DOI: 10.1097/FTD.0000000000000216] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Tseng SH, Lim CP, Chen Q, Tang CC, Kong ST, Ho PC. Evaluating the Relationship between Vancomycin Trough Concentration and 24-Hour Area under the Concentration-Time Curve in Neonates. Antimicrob Agents Chemother 2018;62:e01647-17. [PMID: 29358290 DOI: 10.1128/AAC.01647-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
2 Pham JT. Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates. J Pediatr Pharmacol Ther 2020;25:476-84. [PMID: 32839651 DOI: 10.5863/1551-6776-25.6.476] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Monteiro JF, Hahn SR, Gonçalves J, Fresco P. Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations. Pharmacol Res Perspect 2018;6:e00420. [PMID: 30156005 DOI: 10.1002/prp2.420] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
4 De Rose DU, Cairoli S, Dionisi M, Santisi A, Massenzi L, Goffredo BM, Dionisi-Vici C, Dotta A, Auriti C. Therapeutic Drug Monitoring Is a Feasible Tool to Personalize Drug Administration in Neonates Using New Techniques: An Overview on the Pharmacokinetics and Pharmacodynamics in Neonatal Age. Int J Mol Sci 2020;21:E5898. [PMID: 32824472 DOI: 10.3390/ijms21165898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Mejías-Trueba M, Alonso-Moreno M, Herrera-Hidalgo L, Gil-Navarro MV. Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review. Antibiotics (Basel) 2021;10:347. [PMID: 33805874 DOI: 10.3390/antibiotics10040347] [Reference Citation Analysis]
6 Ma KF, Liu YX, Jiao Z, Lv JH, Yang P, Wu JY, Yang S. Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization. Front Pharmacol 2020;11:563967. [PMID: 33117163 DOI: 10.3389/fphar.2020.563967] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Chung E, Sen J, Patel P, Seto W. Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review. Clin Pharmacokinet 2021;60:985-1001. [PMID: 34002357 DOI: 10.1007/s40262-021-01027-9] [Reference Citation Analysis]
8 Cantey JB. Optimizing the Use of Antibacterial Agents in the Neonatal Period. Paediatr Drugs 2016;18:109-22. [PMID: 26748790 DOI: 10.1007/s40272-015-0161-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]